HWHanfei Wu

Hanfei Wu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hanfei Wu has a total of 32 co-authors. Here are the top co-authors by number of shared publications:

  • Junjun Cao

    Nanjing LivingChip Biotechnology Co., Ltd Nanjing China

    2 shared publications
  • Quan Liu

    Department of Otolaryngology Eye, Ear, Nose and Throat Hospital Fudan University Shanghai China

    2 shared publications
  • Yan Mei

    Nanjing LivingChip Biotechnology Co., Ltd Nanjing China

    2 shared publications
  • Yong Qiao

    Nanjing LivingChip Biotechnology Co., Ltd Nanjing China

    2 shared publications
  • Chuanqian Yi

    School of Nano‐Tech and Nano‐Bionics University of Science and Technology of China Hefei Anhui China

    1 shared publication
  • Danyue Zhi

    School of Nano‐Tech and Nano‐Bionics University of Science and Technology of China Hefei Anhui China

    1 shared publication

Latest Publications

  • Open Access

    Bispecific NK‐Cell Engager Targeting TP53 Mutation Through Integration of a TCR‐mimic Antibody

    by Hanfei Wu, Zhe Zhao, Li Zhang, Xuan Xiong, Mengdie Yang, Weiping Ge, Danyue Zhi, Xiaobin Cao, Chuanqian Yi, Yong Qiao, et al.

    Natural killer (NK) cells are valuable for cancer immunotherapy because they kill tumor cells without prior sensitization or human leukocyte antigen (HLA) restriction. However, their efficacy is often limited by immune‐evasion, especially major histocompatibility complex I (MHC‐I)‐mediated NK cell inhibition. NK cell engagers (NKCEs) can redirect NK cells to tumor for more effective immunotherapy, but most current NKCEs target tumor‐associated antigens (TAAs), risking on‐target, off‐tumor toxicity in clinical applications. Neoantigens, as tumor‐specific antigens (TSAs) arising from somatic mutations and presented by MHC‐I on tumor cell surfaces, represent ideal tumor‐specific target. Here, we engineered NKCEs built on neoantigen‐targeting TCR‐mimic antibodies (TCRm‐Abs) to enhance tumor‐specific NK cell‐mediated cytotoxicity. Using a high‐throughput hydrogel‐based microwell single‐cell chip (HMSC‐chip) coupled with T2 cell‐based de‐selection, we identified C33‐Ab, a functional TCRm‐Ab specific for p53 R175H /HLA‐A*02:01, from ∼500,000 hybridoma cells within 8 weeks. Based on this TCRm‐Ab, we constructed a bispecific NKCE (C33×CD16), a single‐chain diabody (scDb) linking C33‐Ab to an anti‐CD16 scFv. C33×CD16 specifically bridges NK cells with p53 R175H /HLA‐A*02:01‐positive cancer cells. It potently enhanced NK cell‐mediated cytotoxicity in vitro and antitumor efficacy in vivo upon adoptive NK‐cell transfer. This TCRm‐Ab‐based bispecific NKCE offers a promising strategy for tumor‐specific NK cell‐mediated immunotherapy by targeting intracellular oncogenic hotspot mutations.

  • High-throughput generation of patient-derived cancer stem cells for precision medicine using a microwell-chip platform

    by Zhe Zhao, Jie Wang, Xuan Xiong, Sheng Zhang, Mengdie Yang, Hanfei Wu, Xingzhi Liu, Xinxing Ma, Yan Chen, Yong Qiao, et al.

    Substantial evidence indicates that cancer stem cells (CSCs) drive breast cancer (BRC) initiation, progression, therapy resistance, recurrence and metastasis. Evaluating drug efficacy against patient-derived CSCs can advance precision oncology. However, high-throughput isolation of functional CSCs from small clinical samples remains challenging. Tumoursphere formation, arising from the clonal expansion of a single cancer cell, is a standard in vitro method for CSC assay and enrichment. Here we show a microwell cell-chip culture platform that enables rapid, high-throughput generation of uniform micro-tumourspheres (MTSs) from limited BRC specimens, such as puncture biopsies, facilitating functional CSC enrichment and personalized drug testing within 8 days. Single-cell transcriptomics and limiting dilution tumour initiation assay confirm that MTSs recapitulate CSC functionality, uniformity and heterogeneity. MTSs predicted clinical outcomes in 16 patients with BRC with ~93.8% accuracy, underscoring their translational potential for personalized drug testing. Overall, this platform provides a robust tool for CSC-targeted precision medicine.